1. Home
  2. WVE vs VTMX Comparison

WVE vs VTMX Comparison

Compare WVE & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • VTMX
  • Stock Information
  • Founded
  • WVE 2012
  • VTMX 1998
  • Country
  • WVE Singapore
  • VTMX Mexico
  • Employees
  • WVE N/A
  • VTMX N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • VTMX
  • Sector
  • WVE Health Care
  • VTMX
  • Exchange
  • WVE Nasdaq
  • VTMX Nasdaq
  • Market Cap
  • WVE 2.1B
  • VTMX 2.1B
  • IPO Year
  • WVE 2015
  • VTMX 2023
  • Fundamental
  • Price
  • WVE $10.99
  • VTMX $23.99
  • Analyst Decision
  • WVE Strong Buy
  • VTMX Buy
  • Analyst Count
  • WVE 10
  • VTMX 2
  • Target Price
  • WVE $21.60
  • VTMX $33.50
  • AVG Volume (30 Days)
  • WVE 1.0M
  • VTMX 111.6K
  • Earning Date
  • WVE 03-05-2025
  • VTMX 02-12-2025
  • Dividend Yield
  • WVE N/A
  • VTMX 3.01%
  • EPS Growth
  • WVE N/A
  • VTMX 2.33
  • EPS
  • WVE N/A
  • VTMX 0.39
  • Revenue
  • WVE $53,610,000.00
  • VTMX $243,239,612.00
  • Revenue This Year
  • WVE N/A
  • VTMX N/A
  • Revenue Next Year
  • WVE $48.58
  • VTMX $18.89
  • P/E Ratio
  • WVE N/A
  • VTMX $5.89
  • Revenue Growth
  • WVE N/A
  • VTMX 18.11
  • 52 Week Low
  • WVE $3.50
  • VTMX $23.22
  • 52 Week High
  • WVE $16.74
  • VTMX $41.44
  • Technical
  • Relative Strength Index (RSI)
  • WVE 34.06
  • VTMX 40.08
  • Support Level
  • WVE $10.57
  • VTMX $23.83
  • Resistance Level
  • WVE $12.03
  • VTMX $24.62
  • Average True Range (ATR)
  • WVE 0.69
  • VTMX 0.59
  • MACD
  • WVE -0.17
  • VTMX -0.18
  • Stochastic Oscillator
  • WVE 12.54
  • VTMX 22.45

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is a real estate company dedicated to the development and leasing of industrial buildings and distribution centers in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenues is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

Share on Social Networks: